Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
As of today, Moderna(MRNA) shares are valued at $196.45. The company's market cap stands at 79.39B, with a P/E ratio of -25.06.
As of 2026-10-26, Moderna(MRNA) stock has fluctuated between $181.21 and $203.48. The current price stands at $196.45, placing the stock +8.4% above today's low and -3.5% off the high.
The Moderna(MRNA)'s current trading volume is 17.09M, compared to an average daily volume of 20.48M.
During the past year, Moderna(MRNA) stock moved between $22.28 at its lowest and $254.48 at its peak.
During the past year, Moderna(MRNA) stock moved between $22.28 at its lowest and $254.48 at its peak.
MRNA News
Technology Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine Licensing Moderna (MRNA) stock wavered Monday on more muted expectations...
Moderna’s experimental cancer vaccine is getting a reality check, and that’s not necessarily a bad thing. The company’s stock MRNA tumbled about 7.4% at the ma...
Investing Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady Moderna's personalized melanoma vaccine cleared its prima...
Analyst ratings
52%
of 27 ratingsMore MRNA News
Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Moderna today and set a price target of $220.00. Alec Stranahan has given his Hol...
Merck and Moderna reported detailed Phase 3 results for intismeran, an individualized mRNA melanoma therapy given with Keytruda, showing statistically significa...
Moderna's new lab and manufacturing facility in Marlborough, Mass. Mel Musto for WSJ Moderna’s MRNA -1.25 %decrease; down pointing triangle cancer vaccine pass...
Moderna and other pharmaceutical companies are under great pressure to produce successful new drugs. Adam Glanzman / Bloomberg News To the scientific world, Mo...
Biotech company Moderna (MRNA) saw its shares fall by as much as 25% on Thursday, October 22, despite positive results from a late-stage trial of its personaliz...
Moderna and Merck proved their custom cancer vaccine cut the risk of melanoma returning for longer than the cancer drug Keytruda, but it may take several years...
Moderna (MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. is advancing a new study called “A Phase 1/2, Randomized, Placebo-Controlle...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.